In December 2022, the US Department of Health and Human Services (HHS) Office for Civil Rights (OCR) issued guidance on online tracking technology to HIPAA-covered entities.
From streamlining clinical trials to evaluating drug repurposing possibilities for new patient populations and addressing critical supply chain challenges, 2024 will be the year artificial
While global harmonisation remains the holy grail, the reality is that pharmaceutical companies still face significant challenges navigating regulatory differences.
According to Takeda Pharmaceuticals, the average time taken to diagnose a rare disease without technology is 7.6 years, and that comes after countless tests and physician visits.